KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other financing activities: 2016-2023

Historic Other financing activities for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Dec 2023 value amounting to $162.4 million.

  • Amneal Pharmaceuticals' Other financing activities was N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.7 million, marking a year-over-year change of. This contributed to the annual value of $162.4 million for FY2023, which is 9666.39% up from last year.
  • Amneal Pharmaceuticals' Other financing activities amounted to $162.4 million in FY2023, which was up 9,666.39% from $1.7 million recorded in FY2022.
  • In the past 5 years, Amneal Pharmaceuticals' Other financing activities registered a high of $162.4 million during FY2023, and its lowest value of $1.7 million during FY2022.
  • Its 2-year average for Other financing activities is $82.0 million, with a median of $82.0 million in 2022.
  • Data for Amneal Pharmaceuticals' Other financing activities shows a peak YoY spiked of 9,666.39% (in 2023) over the last 5 years.
  • Over the past 3 years, Amneal Pharmaceuticals' Other financing activities (Yearly) stood at $4.1 million in 2020, then reached $1.7 million in 2022, then skyrocketed by 9,666.39% to $162.4 million in 2023.